It’s only fair to share… Asandeutertinib, Osimertinib-d3 CAS 1638281-46-5 N-[2-{2-(dimethylamino)ethylamino}-4-methoxy-5-({4-[1-(2H3)methyl-1H-indol-3-yl]pyrimidin-2-yl}amino)phenyl]prop-2-enamideepidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, antineoplastic MF C28H30. 2H3. N7O2, C28H30D3N7O2 MW 502.6 g/mol Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties.[1][2] Developed by TYK Medicines, this small molecule drug is currently …